T-DXd plus osimertinib for HER2-overexpressing NSCLC after osimertinib resistance: a multicenter real-world study

Authors

Institutions

Publication Details

Journal
BMC Pulmonary Medicine
Published
2026-11-06
DOI
https://doi.org/10.1186/s12890-026-04905-9
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

T-DXd plus osimertinib for HER2-overexpressing NSCLC after osimertinib resistance: a multicenter real-world study

Zhefeng Liu, Yi Hu, An Wang, Tao Li et al.
1 links
BMC Pulmonary Medicine
Lung Cancer Treatments and Mutations
article

T-DXd plus osimertinib for HER2-overexpressing NSCLC after osimertinib resistance: a multicenter real-world study

Zhefeng Liu, Yi Hu, An Wang, Tao Li, Xiao Liu, Tong Zhang, Chang Liu, Feng Li, Min Liu, Chen-chen Ji
article en

Abstract

No abstract available for this paper.
BMC Pulmonary Medicine
Capital Medical University (CN), Nankai University (CN), Chinese PLA General Hospital (CN), First Affiliated Hospital of Chinese PLA General Hospital (CN), Chinese Academy of Agricultural Sciences (CN), Chinese People's Liberation Army (CN)
Good health and well-being
Openalex Percentile: Top 13%
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon